KBC Group
ENTA icon

KBC Group’s Enanta Pharmaceuticals ENTA Stock Holding History

KBC Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,266
Closed -$14K – 1880
2023
Q3 		$14K Sell
1,266
-320
-20% -$5.15K ﹤0.01% 1907
2023
Q2 		$34K Hold
1,586
– – ﹤0.01% 1431
2023
Q1 		$64K Hold
1,586
– – ﹤0.01% 1331
2022
Q4 		$74K Hold
1,586
– – ﹤0.01% 1301
2022
Q3 		$82K Hold
1,586
– – ﹤0.01% 1261
2022
Q2 		$75K Hold
1,586
– – ﹤0.01% 1327
2022
Q1 		$113K Buy
+1,586
New +$103K ﹤0.01% 1156
2019
Q4 		– Sell
-12,843
Closed -$772K – 1509
2019
Q3 		$772K Sell
12,843
-9,104
-41% -$676K 0.01% 956
2019
Q2 		$1.85M Sell
21,947
-1,350
-6% -$121K 0.01% 625
2019
Q1 		$2.23M Sell
23,297
-18,124
-44% -$1.63M 0.02% 594
2018
Q4 		$2.93M Buy
41,421
+20,198
+95% +$1.55M 0.03% 444
2018
Q3 		$1.81M Buy
+21,223
New +$2.13M 0.01% 713

Other funds holding ENTA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KBC Group's ENTA Position: Q4 2023 in Review

KBC Group sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 1,266 shares — an estimated $14K sold.

KBC Group first reported a position in ENTA in Q3 2018 and held it in 12 quarters. The position peaked at $2.93M in Q4 2018. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

  • KBC Group reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • KBC Group sold 1,266 Enanta Pharmaceuticals shares in Q4 2023, an estimated $14K.
  • KBC Group first reported a position in Enanta Pharmaceuticals in Q3 2018 and held it in 12 quarters.
  • KBC Group's Enanta Pharmaceuticals position peaked at $2.93M in Q4 2018.
  • 105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on KBC Group's 13F filing for Q4 2023, filed 13 Feb 2024.